Kristoffer Staal Rohrberg

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong, Steven G. DuBois, Shivaani Kummar et al. · The Lancet Oncology · 2020 · 994 citations · Full text

Medicine, Oncology, Immunotherapy +14

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Padmanee Sharma, Arlene O. Siefker‐Radtke, Filippo de Braud et al. · Journal of Clinical Oncology · 2019 · 243 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +12

Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

Ida Viller Tuxen, Kristoffer Staal Rohrberg, Olga Oestrup et al. · Clinical Cancer Research · 2018 · 95 citations

Medicine, Molecular Medicine, Oncology +17

High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer

Birgitte Bertelsen, Ida Viller Tuxen, Christina W. Yde et al. · npj Genomic Medicine · 2019 · 82 citations · Full text

Life Sciences, Genetics, Oncology +15

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

Alexander Drilon, Geoffrey R. Oxnard, Lori J. Wirth et al. · Journal of Thoracic Oncology · 2019 · 81 citations · Full text

Medicine, Oncology, Cancer Genetics +10